PharmiWeb.com - Global Pharma News & Resources
07-May-2019

Biotest AG: Biotest reaches revenues of EUR 77.5 million in the first quarter 2019

DGAP-News: Biotest AG / Key word(s): Quarter Results

07.05.2019 / 10:00
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

Biotest reaches revenues of EUR 77.5 million in the first quarter 2019

- Guidance confirmed

- Earnings after taxes in the first quarter totalled to EUR -1.2 million


Dreieich, 7 May 2019. In the first quarter of 2019, the Biotest Group reported revenue of EUR 77.5 million. This is a decrease of 11.9 % over the EUR 88.0 million in sales during the same period of the previous year.

EBIT from continuing operations was EUR -9.9 million in the first three months of 2019 (same period of the previous year: EUR -3.0 million). It includes expenses for the Biotest Next Level project of EUR -16.9 million (same period of the previous year: EUR -15.2 million) and income from insurance compensation in the amount of EUR 4 million. The weaker EBIT compared to the previous year is primarily due to lower sales. In addition, a 17.6 % increase in research and development costs had a negative impact on EBIT. The increase is due to the production of clinical material for the development projects IgG Next Generation and Trimodulin.

Earnings after taxes from continuing operations therefore improved to EUR -1.2 million in the first quarter of 2019 compared with EUR -8.1 million in the first quarter of the previous year.

Plasma Service Europe GmbH, Dreieich, Germany, a 100 % subsidiary of Biotest AG, acquired a plasmapheresis centre in Hanover in January 2019. Another centre was opened in Budapest in April 2019. Thus, the Group has expanded its own network of plasma collection stations in Europe to 21 to secure the long-term supply of plasma.

Furthermore, in January 2019 Biotest received the extension of the approved indications of Intratect(R) in 22 European countries to include the neurological indications chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), as well as an extension in the area of secondary immunodeficiencies (SID).

Outlook:
The Biotest Group's outlook has not changed significantly from its presentation in the 2018 Annual Report (page 27 to 30).

Partnering efforts are more complex and time-consuming than expected, therefore the possibility of forecasting without partnering cannot be ruled out. EBIT of EUR -15 to -35 million could then be expected, while EBIT of EUR -5 to +5 million is forecast if partnering agreements are successfully concluded.

The Quarterly statement is available on the company's website at
http://www.biotest.com/de/en/investor_relations/news_and_publications/public
ations/quarterly_reports.cfm

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in certain cancer indications and in systemic lupus erythematodes, an autoimmune disease, which are produced by recombinant technologies. Biotest has more than 1,700 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
 

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.



07.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 807673

 
End of News DGAP News Service

Editor Details

Last Updated: 07-May-2019